Abstract:Background: Enterovirus 71 (EV71), a member of the Enterovirus genus of the Picornaviridae family, is one of the causative pathogens of hand-foot-and-mouth disease (HFMD) and the most common etiological agent isolated from HFMD patients complicated with neurological disorders. EV71 has become an increasingly important neurotropic enterovirus in the post-poliomyelitis eradication era. Effective antiviral agents and vaccines against this virus are currently still under development. We reviewed publications on the development of EV71 vaccines in order to provide an overview of the field. Methods: Fifty-five articles on EV71 vaccine development, published from 1974 to 2009, were collected from Sun Yat-sen University library and reviewed. Results: Various types of vaccine have been developed for EV71. In results published to date, all vaccines for EV71 under development appear to elicit an immune response in rodents or in monkeys. According to the established regulatory standards, it may be relatively easy to acquire a license to use the inactivated virus in order to meet the immediate demands for EV71 control . With regard to the attenuated vaccine, it is critical to increase the genetic stability before clinical use, due to the risk of virulent revertants. The virus-like particle (VLP) vaccine, not only conserving the conformational epitopes, but also having no risk of virulent revertants, is another promising vaccine candidate for EV71, but needs further development. The VP1 capsid protein is the backbone antigen protein for developing subunit vaccine and epitope vaccine; these remain viable potential vaccine strategies worthy of further study and development. Conclusions: The conservation of the three-dimensional structure is important for the EV71 inactivated vaccine and VLP vaccine to induce a strong immune response. To develop EV71 vaccines with a high protection efficacy, strategies such as the use of adjuvant, strong promoters, tissue-specific promoters, and addition of mucosal immune adjuvant should be considered.

Expression and purification of enterovirus type 71 polyprotein P1 using Pichia pastoris system

Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris

Recombinant VP1 protein expressed in Pichia pastoris induces protective immune responses against EV71 in mice

Efficient expression of enterovirus 71 based on virus-like particles vaccine

Process optimization for the rapid production of Enterovirus 71

Expression and Immunogenicity of Novel Subunit Enterovirus 71 Vp1 Antigens

Identification of specific antigenic epitope at N-terminal segment of enterovirus 71 (EV-71) VP1 protein and characterization of its use in recombinant form for early diagnosis of EV-71 infection

[Preparation of monoclonal antibody against enterovirus 71 capsid protein VP1].

Enterovirus71 Virus-Like Particles Produced from Insect Cells and Purified by Multistep Chromatography Elicit Strong Humoral Immune Responses in Mice

Efficient Production of Enterovirus 71 (EV71) Virus-like Particles by Controlling Promoter Strength in Insect Cells

Expression of enterovirus 71 virus-like particles in transgenic enoki (Flammulina velutipes)

Recovery Infectious Enterovirus 71 by Bac-to-Bac Expression System in vitro and in vivo

Enterovirus 71 vaccine: close but still far

The mature EV71 virion induced a broadly cross-neutralizing VP1 antibody against subtypes of the EV71 virus

Biochemical Characterization of Recombinant Enterovirus 71 3C Protease with Fluorogenic Model Peptide Substrates and Development of a Biochemical Assay

VP1 of Enterovirus 71 Protects Mice Against Enterovirus 71 and Coxsackievirus B3 in Lethal Challenge Experiment.

Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71

EV71 Virus-Like Particles Produced by Co-Expression of Capsid Proteins in Yeast Cells Elicit Humoral Protective Response Against EV71 Lethal Challenge

Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses

Prokaryotic Expression of Structural Protein VP1 of Foot-and-mouth disease virus Type O and Analysis of Its Antigenicity

Rational design of a DNA-launched live attenuated vaccine against human enterovirus 71